Literature DB >> 33725121

COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.

Eng Hooi Tan1, Anthony G Sena2,3, Albert Prats-Uribe1, Seng Chan You4, Waheed-Ul-Rahman Ahmed5,6, Kristin Kostka7, Christian Reich7, Scott L Duvall8,9, Kristine E Lynch8,9, Michael E Matheny10,11, Talita Duarte-Salles12, Sergio Fernandez Bertolin12, George Hripcsak13,14, Karthik Natarajan13,14, Thomas Falconer13, Matthew Spotnitz13, Anna Ostropolets13, Clair Blacketer2,3, Thamir M Alshammari15, Heba Alghoul16, Osaid Alser17, Jennifer C E Lane1, Dalia M Dawoud18, Karishma Shah5, Yue Yang19, Lin Zhang20,21, Carlos Areia22, Asieh Golozar23,24, Martina Recalde12,25, Paula Casajust26, Jitendra Jonnagaddala27, Vignesh Subbian28, David Vizcaya29, Lana Y H Lai30, Fredrik Nyberg31, Daniel R Morales32, Jose D Posada33, Nigam H Shah33, Mengchun Gong34, Arani Vivekanantham5, Aaron Abend35, Evan P Minty36, Marc Suchard37, Peter Rijnbeek3, Patrick B Ryan2,13, Daniel Prieto-Alhambra1.   

Abstract

OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza.
METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization.
RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%).
CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Entities:  

Keywords:  COVID-19; Observational Health Data Sciences and Informatics (OHDSI); Observational Medical Outcomes Partnership (OMOP); autoimmune condition; hospitalization; mortality; open science

Mesh:

Year:  2021        PMID: 33725121      PMCID: PMC7989171          DOI: 10.1093/rheumatology/keab250

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.046


  33 in total

1.  Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Authors:  Hussain R Yusuf; W Craig Hooper; Michele G Beckman; Qing C Zhang; James Tsai; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

2.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.

Authors:  Chaomin Wu; Xiaoyan Chen; Yanping Cai; Jia'an Xia; Xing Zhou; Sha Xu; Hanping Huang; Li Zhang; Xia Zhou; Chunling Du; Yuye Zhang; Juan Song; Sijiao Wang; Yencheng Chao; Zeyong Yang; Jie Xu; Xin Zhou; Dechang Chen; Weining Xiong; Lei Xu; Feng Zhou; Jinjun Jiang; Chunxue Bai; Junhua Zheng; Yuanlin Song
Journal:  JAMA Intern Med       Date:  2020-07-01       Impact factor: 21.873

3.  COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study.

Authors:  Kristin M D'Silva; April Jorge; Andrew Cohen; Natalie McCormick; Yuqing Zhang; Zachary S Wallace; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2021-05-01       Impact factor: 15.483

4.  Feasibility and utility of applications of the common data model to multiple, disparate observational health databases.

Authors:  Erica A Voss; Rupa Makadia; Amy Matcho; Qianli Ma; Chris Knoll; Martijn Schuemie; Frank J DeFalco; Ajit Londhe; Vivienne Zhu; Patrick B Ryan
Journal:  J Am Med Inform Assoc       Date:  2015-02-10       Impact factor: 4.497

5.  Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.

Authors:  Rebecca Haberman; Jordan Axelrad; Alan Chen; Rochelle Castillo; Di Yan; Peter Izmirly; Andrea Neimann; Samrachana Adhikari; David Hudesman; Jose U Scher
Journal:  N Engl J Med       Date:  2020-04-29       Impact factor: 91.245

6.  Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis.

Authors:  Catherine R Jutzeler; Lucie Bourguignon; Caroline V Weis; Bobo Tong; Cyrus Wong; Bastian Rieck; Hans Pargger; Sarah Tschudin-Sutter; Adrian Egli; Karsten Borgwardt; Matthias Walter
Journal:  Travel Med Infect Dis       Date:  2020-08-04       Impact factor: 6.211

7.  Comparison between Patients Hospitalized with Influenza and COVID-19 at a Tertiary Care Center.

Authors:  Michael W Donnino; Ari Moskowitz; Garrett S Thompson; Stanley J Heydrick; Rahul D Pawar; Katherine M Berg; Shivani Mehta; Parth V Patel; Anne V Grossestreuer
Journal:  J Gen Intern Med       Date:  2021-03-18       Impact factor: 5.128

8.  Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.

Authors:  Alexis Mathian; Matthieu Mahevas; Julien Rohmer; Mathilde Roumier; Fleur Cohen-Aubart; Blanca Amador-Borrero; Audrey Barrelet; Cecile Chauvet; Thibaud Chazal; Michel Delahousse; Mathilde Devaux; Romain Euvrard; Jehane Fadlallah; Nans Florens; Julien Haroche; Miguel Hié; Laurent Juillard; Raphael Lhote; Thibault Maillet; Gaelle Richard-Colmant; Jean Baptiste Palluy; Micheline Pha; Laurent Perard; Philippe Remy; Etienne Rivière; Damien Sène; Pascal Sève; Capucine Morélot-Panzini; Jean-François Viallard; Jean-Simon Virot; Neila Benameur; Noël Zahr; Hans Yssel; Bertrand Godeau; Zahir Amoura
Journal:  Ann Rheum Dis       Date:  2020-04-24       Impact factor: 27.973

Review 9.  Evidence based management guideline for the COVID-19 pandemic - Review article.

Authors:  Maria Nicola; Niamh O'Neill; Catrin Sohrabi; Mehdi Khan; Maliha Agha; Riaz Agha
Journal:  Int J Surg       Date:  2020-04-11       Impact factor: 6.071

10.  Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.

Authors:  Sara Monti; Silvia Balduzzi; Paolo Delvino; Elisa Bellis; Verdiana Serena Quadrelli; Carlomaurizio Montecucco
Journal:  Ann Rheum Dis       Date:  2020-04-02       Impact factor: 19.103

View more
  8 in total

Review 1.  Biologics for Psoriasis During the COVID-19 Pandemic.

Authors:  Huanhuan Zeng; Siyu Wang; Ling Chen; Zhu Shen
Journal:  Front Med (Lausanne)       Date:  2021-12-06

Review 2.  COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.

Authors:  Jelka Kramarič; Rok Ješe; Matija Tomšič; Žiga Rotar; Alojzija Hočevar
Journal:  Clin Rheumatol       Date:  2022-04-02       Impact factor: 3.650

3.  Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.

Authors:  Kristin Kostka; Talita Duarte-Salles; Albert Prats-Uribe; Anthony G Sena; Andrea Pistillo; Sara Khalid; Lana Y H Lai; Asieh Golozar; Thamir M Alshammari; Dalia M Dawoud; Fredrik Nyberg; Adam B Wilcox; Alan Andryc; Andrew Williams; Anna Ostropolets; Carlos Areia; Chi Young Jung; Christopher A Harle; Christian G Reich; Clair Blacketer; Daniel R Morales; David A Dorr; Edward Burn; Elena Roel; Eng Hooi Tan; Evan Minty; Frank DeFalco; Gabriel de Maeztu; Gigi Lipori; Hiba Alghoul; Hong Zhu; Jason A Thomas; Jiang Bian; Jimyung Park; Jordi Martínez Roldán; Jose D Posada; Juan M Banda; Juan P Horcajada; Julianna Kohler; Karishma Shah; Karthik Natarajan; Kristine E Lynch; Li Liu; Lisa M Schilling; Martina Recalde; Matthew Spotnitz; Mengchun Gong; Michael E Matheny; Neus Valveny; Nicole G Weiskopf; Nigam Shah; Osaid Alser; Paula Casajust; Rae Woong Park; Robert Schuff; Sarah Seager; Scott L DuVall; Seng Chan You; Seokyoung Song; Sergio Fernández-Bertolín; Stephen Fortin; Tanja Magoc; Thomas Falconer; Vignesh Subbian; Vojtech Huser; Waheed-Ul-Rahman Ahmed; William Carter; Yin Guan; Yankuic Galvan; Xing He; Peter R Rijnbeek; George Hripcsak; Patrick B Ryan; Marc A Suchard; Daniel Prieto-Alhambra
Journal:  Clin Epidemiol       Date:  2022-03-22       Impact factor: 4.790

Review 4.  COVID-19 disease and autoimmune disorders: A mutual pathway.

Authors:  Mohammed Al-Beltagi; Nermin Kamal Saeed; Adel Salah Bediwy
Journal:  World J Methodol       Date:  2022-07-20

5.  Nineteen months into the pandemic, what have we learned about COVID-19-related outcomes in patients with psoriasis?

Authors:  Khalaf Kridin; Yochai Schonmann; Erez Onn; Dana Tzur Bitan; Orly Weinstein; Eran Shavit; Arnon D Cohen
Journal:  J Cosmet Dermatol       Date:  2022-09-03       Impact factor: 2.189

Review 6.  Blueprint for harmonising unstandardised disease registries to allow federated data analysis: prepare for the future.

Authors:  Johannes A Kroes; Aruna T Bansal; Emmanuelle Berret; Nils Christian; Andreas Kremer; Anna Alloni; Matteo Gabetta; Chris Marshall; Scott Wagers; Ratko Djukanovic; Celeste Porsbjerg; Dominique Hamerlijnck; Olivia Fulton; Anneke Ten Brinke; Elisabeth H Bel; Jacob K Sont
Journal:  ERJ Open Res       Date:  2022-10-04

7.  Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States.

Authors:  Xiaomeng Yue; Yizhou Ye; Yookyung C Choi; Dongmu Zhang; Whitney S Krueger
Journal:  Adv Ther       Date:  2022-09-25       Impact factor: 4.070

8.  Defining COVID-19-associated hyperinflammatory syndrome in specific populations.

Authors:  Brandon J Webb
Journal:  Lancet Rheumatol       Date:  2021-05-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.